Adia Nutrition Inc. Delivers Explosive Third Quarter Growth: Revenue Surges Over 100% from Prior Quarter, with Remarkable Profit Margin Exceeding 20%
Adia Nutrition (OTCQB: ADIA) reported preliminary Q3 results for the quarter ended September 30, 2025 showing a revenue increase of more than 100% quarter‑over‑quarter and a profit margin exceeding 20%. Growth was attributed to higher sales of umbilical cord stem cells and exosome therapies across clinical partnerships, direct‑to‑consumer channels, and national expansion. Management described the quarter as a milestone for the company and said full reviewed financial statements will be posted on OTC Markets and filed by on or before November 15, 2025.
Contact and partnership inquiries directed to CEO Larry Powalisz.
Adia Nutrition (OTCQB: ADIA) ha riportato i risultati preliminari del terzo trimestre per il periodo terminato il 30 settembre 2025, mostrando un aumento della redditività superiore al 100% su base trimestrale e un margine di profitto superiore al 20%. La crescita è stata attribuita a maggiori vendite di cellule staminali del cordone ombelicale e terapie con esosome attraverso collaborazioni cliniche, canali diretti al consumatore e espansione nazionale. La gestione ha descritto il trimestre come una pietra miliare per l'azienda e ha detto che i bilanci finanziari pienamente revisionati saranno pubblicati su OTC Markets e depositati entro il 15 novembre 2025.
Per informazioni su contatti e partnership rivolgersi al CEO Larry Powalisz.
Adia Nutrition (OTCQB: ADIA) reportó resultados preliminares del tercer trimestre correspondientes al periodo terminado el 30 de septiembre de 2025, mostrando un incremento de ingresos de más del 100% trimestre a trimestre y un margen de beneficio superior al 20%. El crecimiento se atribuyó a mayores ventas de células madre de la cuerda umbilical y terapias con exosomas a través de asociaciones clínicas, canales directos al consumidor y expansión nacional. La dirección describió el trimestre como un hito para la empresa y dijo que los estados financieros completamente revisados serán publicados en OTC Markets y presentados a más tardar el 15 de noviembre de 2025.
Para consultas de contacto y asociaciones dirigirse al CEO Larry Powalisz.
Adia Nutrition (OTCQB: ADIA)는 2025년 9월 30일 종료된 분기에 대한 예비 3분기 실적을 발표했고, 분기 대비 100% 이상 매출 증가와 수익률 20%를 초과하는 이익 마진을 보였습니다. 성장은 임신제대혈 줄기세포 및 외소체 치료법의 매출 증가를 임상 제휴, 직판 채널, 전국 확장에 기인한 것으로 설명되었습니다. 경영진은 이번 분기를 회사의 이정표로 평가했고, 완전 검토된 재무제표가 2025년 11월 15일 또는 그 전에 OTC Markets에 게시 및 제출될 예정이라고 밝혔습니다.
문의 및 파트너십 문의는 CEO Larry Powalisz에게 보내주십시오.
Adia Nutrition (OTCQB: ADIA) a publié des résultats préliminaires du troisième trimestre pour le trimestre clos le 30 septembre 2025, montrant une augmentation du chiffre d'affaires de plus de 100 % en glissement trimestriel et une marge bénéficiaire supérieure à 20 %. La croissance a été attribuée à des ventes accrues de cellules souches du cordon ombilical et de thérapies par exosomes à travers des partenariats cliniques, des canaux directs au consommateur et une expansion nationale. La direction a décrit le trimestre comme une étape importante pour l'entreprise et a déclaré que les états financiers entièrement examinés seront publiés sur OTC Markets et déposés au plus tard le 15 novembre 2025.
Pour les demandes de contact et de partenariat, veuillez vous adresser au PDG Larry Powalisz.
Adia Nutrition (OTCQB: ADIA) berichtete vorläufige Ergebnisse des dritten Quartals für das Quartal zum 30. September 2025, wobei ein Umsatzwachstum von mehr als 100% gegenüber dem Vorquartal und eine Gewinnmarge von über 20% verzeichnet wurden. Das Wachstum wurde auf höhere Verkäufe von Nabelschnur-Blutstammzellen und Exosomen-Therapien in klinischen Partnerschaften, Direct-to-Consumer-Kanälen und nationaler Expansion zurückgeführt. Das Management beschrieb das Quartal als Meilenstein für das Unternehmen und erklärte, dass vollständig geprüfte Finanzabschlüsse auf OTC Markets veröffentlicht und bis spätestens am 15. November 2025 eingereicht werden.
Anfragen zu Kontakten und Partnerschaften richten Sie bitte an den CEO Larry Powalisz.
Adia Nutrition (OTCQB: ADIA) قد أصدرت نتائج أولية للربع الثالث للربع المنتهي في 30 سبتمبر 2025 تُظهر زيادة في الإيرادات تتجاوز 100% مقارنةً بالربع السابق و هامش ربح يتجاوز 20%. عُزي النمو إلى ارتفاع مبيعات الخلايا الجذعية من الحبل السري وعلاجات الإكسوسومات عبر الشراكات السريرية والقنوات المباشرة للمستهلك والتوسع على الصعيد الوطني. وصف الإدارة الربع بأنه علامة فارقة للشركة وقالت إن البيانات المالية المراجعة بالكامل ستُنشَر على OTC Markets وتُقدَّم قبل 15 نوفمبر 2025.
للاستفسارات عن الاتصالات والشراكات، الرجاء توجيهها إلى الرئيس التنفيذي لاري باواليسك.
Adia Nutrition (OTCQB: ADIA) 已公布截至2025年9月30日季度结束的初步第三季度业绩，显示 环比增长超过100%的收入增长和 超过20%的利润率。增长归因于脐带血干细胞和外泌体疗法在临床伙伴关系、直接面向消费者渠道和全国扩张中的销售增长。管理层将该季度描述为公司的一座里程碑，并表示经全面审阅的财务报表将公布在 OTC Markets 上并在 2025 年 11 月 15 日或之前提交。
有关联系及合作咨询请联系首席执行官 Larry Powalisz。
- Revenue grew by >100% QoQ in Q3 2025
- Profit margin reported at >20% for the quarter
- Sales expansion across clinical, DTC, and national channels
- Results are preliminary and will be subject to review before the Nov 15, 2025 filing
Winter Park, Florida--(Newsfile Corp. - October 8, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a trailblazer in umbilical cord stem cells and exosome sales and therapies, today announced phenomenal preliminary financial results for the third quarter ended September 30, 2025. The company achieved a monumental revenue increase of more than
"This third quarter marks a historic leap forward for Adia Nutrition," said CEO Larry Powalisz. "Doubling our revenue in a single quarter while achieving such a robust profit margin is a powerful reflection of our team's dedication, our cutting-edge therapeutic portfolio, and the trust of our rapidly expanding customer base. We're not just growing, we're redefining what's possible in the regenerative medicine space."
Key highlights from the preliminary third quarter results include:
Revenue Surge: Revenue grew by over
100% from the second quarter, fueled by skyrocketing sales of umbilical cord stem cells and exosomes across clinical partnerships, direct-to-consumer channels, and national market expansion.Profit Triumph: A profit margin exceeding
20% , showcasing operational efficiency, strategic investments, and the strength of high-margin therapeutic offerings resonating with patients and healthcare providers.Unstoppable Momentum: These results build on Adia Nutrition's year-to-date success, positioning the company for record-breaking annual growth and enhanced shareholder value.
The full third quarter financial report, including reviewed statements and detailed metrics, will be released and posted on the OTC Markets website (www.otcmarkets.com) on or before November 15, 2025, and filed with the appropriate regulatory bodies.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269471
FAQ
What did Adia Nutrition (ADIA) report for Q3 2025 on October 8, 2025?
When will Adia Nutrition file the reviewed Q3 2025 financial statements for ADIA?
What drove the Q3 2025 revenue surge for ADIA?
How material is ADIA's reported profit margin in Q3 2025 for investors?
Are ADIA's Q3 2025 results final and audited?
How can investors or partners contact Adia Nutrition about Q3 results or licensing?
